We tested HMT inhibitor 3-Deazaneplanocin A and HDAC inhibitor Belinostat in combination with Idarubicin and Retinoic acid in vitro (NB4 cell line) and ex vivo (APL patient bone marrow cell samples). Here, HDAC9 is linked to acute promyelocytic leukemia.